Murine models for human immunodeficiency virus type 1-associated dementia: The development of new treatment testing paradigms

Journal of NeuroVirology

Volumn 8, Issue SUPPL. 2, 2002, Pages 49-52

  Persidsky, Yuri ^a   Gendelman, Howard E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Animal model; HIV encephalitis; Neuronal damage; Therapeutics

Indexed keywords

ABACAVIR; ANTIINFLAMMATORY AGENT; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LAMIVUDINE; NEUROPROTECTIVE AGENT; NEUROTOXIN; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BASAL GANGLION; BEHAVIOR DISORDER; BRAIN NERVE CELL; BRAIN TISSUE; CELL DESTRUCTION; CELLULAR IMMUNITY; COGNITIVE DEFECT; CYTOTOXICITY; DEMENTIA; DISEASE ASSOCIATION; DISEASE SEVERITY; ENCEPHALITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; MACROPHAGE; MOUSE; NERVE CELL LESION; NEUROPATHOLOGY; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS ENCEPHALITIS; VIRUS LOAD;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MURINAE;

EID: 0036947992     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280290167993     Document Type: Review

References (22)

1. Dore GJ, Correll PK, et al (1999). Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13: 1249-1253.
2. Gendelman HE, Persidsky Y, et al (1997). The neuropathogenesis of the AIDS dementia complex. AIDS 11(suppl A): S35-S45.
3. Kaul M, Garden GA, et al (2001). Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410: 988-994.
4. King DL, Arendash GW, et al (1999). Progressive and gender-dependent cognitive impairment in the APP-(SW) transgenic mouse model for Alzheimer's disease. Behav Brain Res 103: 145-162.
5. Koenig S, Gendelman HE, et al (1986). Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089-1093.
6. Limoges J, Persidsky Y, et al (2000). Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice. Neurology 54: 379-389.
7. Limoges J, Poluektova L, et al (2001). The efficacy of potent anti-retroviral drug combinations tested in a murine model of HIV-1 encephalitis. Virology 281: 21-34.
8. Maschke M, Kastrup O, et al (2000). Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 69: 376-380.
9. McArthur JC, Hoover DR, et al (1993). Dementia in AIDS patients: incidence and risk factors. Multicenter AIDS Cohort Study. Neurology 43: 2245-2252.
10. Persidsky Y, Buttini M, et al (1997). An analysis of HIV-1-associated inflammatory products in brain tissue of humans and SCID mice with HIV-1 encephalitis. J Neurovirol 3: 401-416.
11. Persidsky Y, Ghorpade A, et al (1999). Microglial and astrocyte chemokines regulate monocyte migration through blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol 155: 1599-1611.
12. Persidsky Y, Limoges J, et al (1996). Human immunodeficiency virus encephalitis in SCID mice [see comments]. Am J Pathol 149: 1027-1053.
13. Persidsky Y, Limoges J, et al (2001). Reduction in glial immunity and neuropathology by a PAF antagonist and an MMP and TNFalpha inhibitor in SCID mice with HIV-1 encephalitis. J Neuroimmunol 114: 57-68.
14. Persidsky Y, Zheng J, et al (2000). Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia. J Leukoc Biol 68: 413-422.
15. Pitcher CJ, Quittner C, et al (1999). HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5: 518-525.
16. Poluektova L, Moran T, et al (2001). The regulation of alpha chemokines during HIV-1 infection and leukocyte activation: relevance for HIV-1-associated dementia. J Neuroimmunol 120: 112-128.
17. Poluektova LY, Munn DH, et al (2002). Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol 168: 3941-3949.
18. Sacktor N, Lyles RH, et al (2001). HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998. Neurology 56: 257-260.
19. Sopper S, Sauer U, et al (1998). Protective role of the virus-specific immune response for development of severe neurologic signs in simian immunodeficiency virus-infected macaques. J Virol 72: 9940-9947.
20. Trimble LA, Shankar P, et al (2000). Human immunodeficiency virus-specific circulating CD8 T lymphocytes have down-modulated CD3zeta and CD28, key signaling molecules for T-cell activation. J Virol 74: 7320-7330.
21. Wiley CA, Schrier RD, et al (1986). Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 83: 7089-7093.
22. Zink WE, Anderson E, et al (2002). Impaired spatial cognition and synaptic potentiation in a murine model of human immunodeficiency virus type 1 encephalitis. J Neurosci 22: 2096-2105.